JP2020510646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510646A5 JP2020510646A5 JP2019545316A JP2019545316A JP2020510646A5 JP 2020510646 A5 JP2020510646 A5 JP 2020510646A5 JP 2019545316 A JP2019545316 A JP 2019545316A JP 2019545316 A JP2019545316 A JP 2019545316A JP 2020510646 A5 JP2020510646 A5 JP 2020510646A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 105
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 239000000427 antigen Substances 0.000 claims description 51
- 102000036639 antigens Human genes 0.000 claims description 51
- 108091007433 antigens Proteins 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000001608 potassium adipate Substances 0.000 claims description 2
- 239000001601 sodium adipate Substances 0.000 claims description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 13
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 13
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 13
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 13
- 241000282412 Homo Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023000416A JP2023052214A (ja) | 2017-02-20 | 2023-01-05 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2025002125A JP2025061059A (ja) | 2017-02-20 | 2025-01-07 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461145P | 2017-02-20 | 2017-02-20 | |
| US62/461,145 | 2017-02-20 | ||
| PCT/US2018/018768 WO2018152516A1 (en) | 2017-02-20 | 2018-02-20 | Proteins binding cd33, nkg2d and cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000416A Division JP2023052214A (ja) | 2017-02-20 | 2023-01-05 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510646A JP2020510646A (ja) | 2020-04-09 |
| JP2020510646A5 true JP2020510646A5 (enExample) | 2021-04-15 |
Family
ID=63169992
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545316A Pending JP2020510646A (ja) | 2017-02-20 | 2018-02-20 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2023000416A Pending JP2023052214A (ja) | 2017-02-20 | 2023-01-05 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2025002125A Pending JP2025061059A (ja) | 2017-02-20 | 2025-01-07 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000416A Pending JP2023052214A (ja) | 2017-02-20 | 2023-01-05 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2025002125A Pending JP2025061059A (ja) | 2017-02-20 | 2025-01-07 | Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210130471A1 (enExample) |
| EP (1) | EP3583131A4 (enExample) |
| JP (3) | JP2020510646A (enExample) |
| KR (1) | KR20190120775A (enExample) |
| CN (1) | CN110573530A (enExample) |
| AU (1) | AU2018220734B2 (enExample) |
| BR (1) | BR112019017277A2 (enExample) |
| CA (1) | CA3054078A1 (enExample) |
| IL (1) | IL268790A (enExample) |
| MA (1) | MA47508A (enExample) |
| SG (1) | SG11201907638QA (enExample) |
| WO (1) | WO2018152516A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3579848B1 (en) | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| SG11202103832SA (en) * | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| CN113121697B (zh) * | 2019-12-31 | 2023-06-09 | 周易 | Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用 |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| KR20230047112A (ko) * | 2020-07-03 | 2023-04-06 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 다작용성 직교성 단백질 키메라 |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| CN115197330B (zh) * | 2021-04-14 | 2023-04-28 | 广州百暨基因科技有限公司 | 同时靶向cll1和cd33的嵌合抗原受体及其应用 |
| CN116948029A (zh) * | 2022-04-20 | 2023-10-27 | 南京融捷康生物科技有限公司 | 一种包含IgG类Fc区变体的抗体及其用途 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025245271A1 (en) * | 2024-05-21 | 2025-11-27 | Dragonfly Therapeutics, Inc. | Anti-nkg2d antibodies and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| WO2014145806A2 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins |
| US10174117B2 (en) * | 2013-06-11 | 2019-01-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| US20170022291A1 (en) * | 2014-04-01 | 2017-01-26 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| SG10201913324PA (en) * | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| US10851149B2 (en) * | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
| EP2985294A1 (en) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| DK3029137T3 (en) * | 2014-12-06 | 2019-04-08 | Gemoab Monoclonals Gmbh | GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF |
| EP3258967A4 (en) * | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| EP4424326A3 (en) * | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| EP3579848B1 (en) * | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
-
2018
- 2018-02-20 US US16/486,921 patent/US20210130471A1/en not_active Abandoned
- 2018-02-20 CA CA3054078A patent/CA3054078A1/en active Pending
- 2018-02-20 MA MA047508A patent/MA47508A/fr unknown
- 2018-02-20 AU AU2018220734A patent/AU2018220734B2/en not_active Expired - Fee Related
- 2018-02-20 JP JP2019545316A patent/JP2020510646A/ja active Pending
- 2018-02-20 WO PCT/US2018/018768 patent/WO2018152516A1/en not_active Ceased
- 2018-02-20 EP EP18753685.9A patent/EP3583131A4/en active Pending
- 2018-02-20 BR BR112019017277-7A patent/BR112019017277A2/pt unknown
- 2018-02-20 SG SG11201907638QA patent/SG11201907638QA/en unknown
- 2018-02-20 CN CN201880026148.9A patent/CN110573530A/zh active Pending
- 2018-02-20 KR KR1020197026921A patent/KR20190120775A/ko not_active Ceased
-
2019
- 2019-08-19 IL IL26879019A patent/IL268790A/en unknown
-
2023
- 2023-01-05 JP JP2023000416A patent/JP2023052214A/ja active Pending
-
2025
- 2025-01-07 JP JP2025002125A patent/JP2025061059A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510646A5 (enExample) | ||
| JP2020507328A5 (enExample) | ||
| JP2023052214A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020521448A5 (enExample) | ||
| JP2021098733A5 (enExample) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2021191763A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2018046872A5 (enExample) | ||
| JP2020529410A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| JP2020522473A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2020514277A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| RU2008129080A (ru) | Средства и способы лечения опухолевых заболеваний | |
| JP2018510617A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 |